LUNG Earnings Date: Mar 3, 2027 (Estimated) — Pulmonx Corporation
NASDAQ · Healthcare · Medical Devices
Updated
When is LUNG's next earnings date?
Pulmonx Corporation (LUNG) is expected to report Q4 2026 earnings on Wednesday, March 3, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.22 on revenue of $25.3M.
How did LUNG do in its last earnings report?
In its most recent report on Oct 27, 2026 (Q3 2026), Pulmonx Corporation posted EPS of -$0.19 versus the -$0.26 estimate, a beat of 26.0%. Revenue was $22.8M against a $21.9M estimate. The stock's 1-day post-earnings move was +27.3%.
How much does LUNG stock move after earnings?
LUNG beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 23.6% (up or down) in the day after earnings.
About Pulmonx Corporation
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
🤖 AI Earnings Analysis
Pulmonx’s Q3 revenue narrowly beat at $23M versus $22M expected, but growth was only 5% year over year—not the reported 801% figure—and a $15M operating loss underscores persistent profitability concerns.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-27 | Q3 2026 | -0.26 | -0.19 | +25.96% | $22.8M | ✅ Beat | +27.27% | — | — |
| 2026-07-29 | Q2 2026 | -0.28 | -0.24 | +14.29% | $22.8M | ✅ Beat | +28.80% | +58.40% | +93.60% |
| 2026-04-29 | Q1 2026 | -0.33 | -0.33 | +0.00% | $20.6M | ➖ Inline | +6.67% | +7.50% | +37.50% |
| 2026-03-04 | Q4 2025 | -0.39 | -0.25 | +35.90% | $22.6M | ✅ Beat | +11.81% | +24.65% | -7.64% |
| 2025-11-12 | Q3 2025 | -0.41 | -0.34 | +17.07% | $21.5M | ✅ Beat | -18.88% | -29.59% | +29.08% |
| 2025-07-30 | Q2 2025 | -0.40 | -0.38 | +5.00% | $23.9M | ✅ Beat | -41.59% | -48.89% | -44.13% |
| 2025-04-30 | Q1 2025 | -0.40 | -0.36 | +10.00% | $22.5M | ✅ Beat | -21.95% | -23.81% | -29.61% |
| 2025-02-19 | Q4 2024 | -0.45 | -0.33 | +26.67% | $23.8M | ✅ Beat | +32.23% | +38.86% | +15.96% |
Showing last 8 quarters.